Co-Diagnostics, Inc. Cash Flow Statement
CODX|9 years of annual SEC 10-K data (FY2017-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 9 fiscal years. All figures from audited SEC 10-K filings.
Co-Diagnostics, Inc. used $29M in operating cash flow and negative free cash flow of $30M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -6.63 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$46.9M | -$37.6M | -$35.3M | $36.7M | $42.5M | -$6.2M | -$6.3M | -$7.0M | -$1.9M |
| Depreciation & Amortization | $1.1M | $1.4M | $1.2M | $335.4K | $138.6K | $65.9K | $50.8K | $45.8K | $37.5K |
| Operating Cash Flow | -$29.1M | -$29.2M | -$22.1M | $41.1M | $28.2M | -$5.5M | -$4.1M | -$3.2M | -$1.3M |
| Capital Expenditures | $700.0K | $748.4K | $1.4M | $669.5K | $774.4K | $113.2K | $41.3K | $129.3K | $12.2K |
| Free Cash Flow | -$29.8M | -$29.9M | -$23.4M | $40.4M | $27.4M | -$5.6M | -$4.1M | -$3.3M | -$1.3M |
| Share Buybacks | - | - | $1.4M | $14.2M | - | - | - | - | - |
| FCF Margin | -4793.2% | -763.8% | -344.2% | 41.3% | 36.7% | -2622.8% | -10326.4% | -43601.0% | -17286.7% |